Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CORTECH BRADYCOR SEPSIS TRIAL SHOWS NO SURVIVAL IMPROVEMENT

Executive Summary

CORTECH BRADYCOR SEPSIS TRIAL SHOWS NO SURVIVAL IMPROVEMENT in patients with systemic inflammatory response syndrome and presumed sepsis, the company reported July 21. Announcing results of its Phase II trial of the bradykinin antagonist, Cortech said "the primary analysis" of the trial results "did not demonstrate a clinically meaningful reduction in risk-adjusted 28-day survival." The 500-patient, 47-site study tested three dosing levels of three-day Bradycor infusion against placebo. "No safety concerns emerged" in the study, Cortech said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024800

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel